Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Zhou, Caicun, Prof, Wu, Yi-Long, Prof, Chen, Gongyan, Prof, Feng, Jifeng, Prof, Liu, Xiao-Qing, Prof, Wang, Changli, Prof, Zhang, Shucai, Prof, Wang, Jie, Prof, Zhou, Songwen, MD, Ren, Shengxiang, MD, Lu, Shun, Prof, Zhang, Li, Prof, Hu, Chengping, Prof, Hu, Chunhong, Prof, Luo, Yi, Prof, Chen, Lei, Prof, Ye, Ming, Prof, Huang, Jianan, Prof, Zhi, Xiuyi, Prof, Zhang, Yiping, Prof, Xiu, Qingyu, Prof, Ma, Jun, Prof, You, Changxuan, Prof
Published in The lancet oncology (01.08.2011)
Published in The lancet oncology (01.08.2011)
Get full text
Journal Article